0000899243-21-003676.txt : 20210128
0000899243-21-003676.hdr.sgml : 20210128
20210128204043
ACCESSION NUMBER: 0000899243-21-003676
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210126
FILED AS OF DATE: 20210128
DATE AS OF CHANGE: 20210128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Satvat Ali J.
CENTRAL INDEX KEY: 0001621788
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 21567526
MAIL ADDRESS:
STREET 1: C/O KOHLBERG KRAVIS ROBERTS & CO.
STREET 2: 2800 SAND HILL ROAD, SUITE 200
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-26
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001621788
Satvat Ali J.
C/O KOHLBERG KRAVIS ROBERTS & CO. L.P.
2800 SAND HILL ROAD
MENLO PARK
CA
94025
1
0
0
0
Stock Option (Right to Buy)
26.21
2021-01-26
4
A
0
39851
0.00
A
2030-05-27
Common Stock
39851
39851
D
Stock Option (Right to Buy)
16.68
2021-01-26
4
A
0
39851
0.00
A
2029-06-12
Common Stock
39851
39851
D
Stock Option (Right to Buy)
10.99
2021-01-26
4
A
0
79702
0.00
A
2028-07-01
Common Stock
79702
79702
D
Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among Eidos Therapeutics, Inc. ("Eidos"), the Issuer, Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of the Issuer ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of the Issuer ("Merger Sub II"), Merger Sub was merged with and into Eidos, with Eidos continuing as the surviving corporation and immediately thereafter, Eidos was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). The option became fully vested immediately prior to the Effective Time.
(Continued from Footnote 1) At the Effective Time, each such option was cancelled, assumed by the Issuer and replaced with an option to purchase 1.85 shares of the Issuer's common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such stock option is subject to the same terms and conditions applicable to the Eidos option immediately prior to the Effective Time.
The stock option was fully vested. At the Effective Time, each such option was cancelled, assumed by the Issuer and replaced with an option to purchase 1.85 shares of the Issuer's common stock at an exercise price per share of the Issuer's common stock equal to the exercise price per share of the Eidos option divided by 1.85. Such stock option is subject to the same terms and conditions applicable to the Eidos option immediately prior to the Effective Time.
/s/ Tara Condon, Attorney-in-Fact
2021-01-28